Market News
- PRO-1107 by ProfoundBio Suzhou for Solid Tumor: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 20, 2024
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Solid Tumor.
- PRO-1107 by ProfoundBio Suzhou for Bladder Cancer: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 20, 2024
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Bladder Cancer.
- PRO-1107 by ProfoundBio Suzhou for Gastric Cancer: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 20, 2024
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Gastric Cancer.
- DF-4101 by AbbVie for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 20, 2024
DF-4101 is under clinical development by AbbVie and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
- DF-4101 by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 20, 2024
DF-4101 is under clinical development by AbbVie and currently in Phase I for Non-Small Cell Lung Cancer.
- DF-4101 by AbbVie for Renal Cell Carcinoma: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 20, 2024
DF-4101 is under clinical development by AbbVie and currently in Phase I for Renal Cell Carcinoma.
- DF-4101 by AbbVie for Solid Tumor: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 20, 2024
DF-4101 is under clinical development by AbbVie and currently in Phase I for Solid Tumor.
- RG-6315 by Genentech USA for Inflammation: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 20, 2024
RG-6315 is under clinical development by Genentech USA and currently in Phase I for Inflammation.
- GH-21 by HUYA Bioscience International for Non-Small Cell Lung Cancer: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 20, 2024
GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Non-Small Cell Lung Cancer.
- HU-6 by Rivus Pharmaceuticals for Hypertriglyceridemia: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 20, 2024
HU-6 is under clinical development by Rivus Pharmaceuticals and currently in Phase II for Hypertriglyceridemia.
- Texas Biomed Developing Potential Bird Flu Vaccineby OncLive articles on April 19, 2024
While human infections of the virus are rare, a strain recently appeared in dairy cows before infecting a human in Texas.
- Alvotech deal could heighten biosimilar pressure on Humiraby Jonathan Gardner (BioPharma Dive – Latest News) on April 19, 2024
The agreement may help Alvotech capitalize on a recent policy shift by CVS that has driven major market share declines for AbbVie’s blockbuster drug.
- Essential Pharma Acquires Reminyl, a Cholinesterase Inhibitor to Treat Mild to Moderately Severe Dementia from Janssen Pharmaceutica NVby OncLive articles on April 19, 2024
Acquisition includes rights to marketing in the European Economic Area, Thailand, South Korea, and other regions for oral treatment of mild to moderately severe dementia associated with Alzheimer disease.
- FDA Approves Takeda’s Subcutaneous Form of Entyvio as a Maintenance Therapy in Adults with Moderately to Severe Crohn Diseaseby OncLive articles on April 19, 2024
Approval was based on positive data from Takeda’s Phase III VISIBLE 2 study, which displayed long-term clinical remission in approximately half of patients with Crohn disease receiving Entyvio.
- Roche wins FDA OK for Alecensa in early lung cancerby Ben Fidler (BioPharma Dive – Latest News) on April 19, 2024
Alecensa is the first targeted drug available after surgery for people with ALK-positive lung tumors, who are at high risk for brain metastases.
- FDA Approves Roche’s Alecensa as Adjuvant Treatment for ALK-Positive Early-Stage NSCLCby OncLive articles on April 19, 2024
Data from the Phase III ALINA trial show that Alecensa reduced the risk of disease recurrence or death by 76% vs. platinum-based chemotherapy in patients with completely resected IB to IIIA ALK-positive non–small cell lung cancer.
- Will Synthetic, AI-Based Digital Humans Change Pharma and Life Sciences? Q&A with Abid Rahman, SVP Innovation, EVERSANAby OncLive articles on April 19, 2024
Rahman discusses the new opportunities that digital twins present to researchers.
- Lene Oddershede Discusses Upcoming Projects from the Novo Nordisk Foundationby OncLive articles on April 19, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Lene Oddershede, SVP, Natural & Technical Sciences, Novo Nordisk Foundation offers a synopsis of upcoming projects from the Novo Nordisk Foundation.
- Lessons Learned on the Art and Science of Product Commercializationby OncLive articles on April 19, 2024
Insight that can help smaller biotech companies prepare for commercialization in the world of big pharma.
- Pharma Pulse 4/19/24: The Health and Healthcare of Gen-Z, Long-Acting Drugs May Revolutionize HIV Prevention/Treatment & moreby OncLive articles on April 19, 2024
The latest news for pharma industry insiders.